Chemed price target raised to $667 from $633 at RBC Capital

RBC Capital raised the firm’s price target on Chemed (CHE) to $667 from $633 and keeps an Outperform rating on the shares after its Q4 earnings beat last month. Chemed expects VITAS ADC momentum to continue in 2025 with the outlook calling for 8.5%-9.0% growth, and the firm is encouraged that Roto-Rooter appears to be normalizing after several quarters of declining revenue, the analyst tells investors in a research note. RBC adds that the company expects modest commercial demand recovery this year for Roto-Rooter leading to low-single-digit growth.